公开(公告)号：US20230011269A1

公开(公告)日：2023-01-12

申请号：US17808390

申请日：2022-06-23

申请人： Ardea Biosciences, Inc. ,  AstraZeneca AB

发明人： Joanne REILAND WAKEMAN ,  Colin ROWLINGS ,  Sha LIU ,  Gerry BURKE ,  Christian VON CORSWANT ,  Christer TANNERGREN ,  Johan HJÄRTSTAM

IPC分类号： A61K9/20 ,  A61K9/14 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K31/426 ,  A61K31/4418 ,  A61K45/06

摘要： The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.

公开(公告)号：US20210113472A1

公开(公告)日：2021-04-22

申请号：US17007041

申请日：2020-08-31

申请人： Ardea Biosciences, Inc. ,  AstraZeneca AB

发明人： Joanne REILAND WAKEMAN ,  Colin ROWLINGS ,  Sha LIU ,  Gerry BURKE ,  Christian VON CORSWANT ,  Christer TANNERGREN ,  Johan HJÄRTSTAM

IPC分类号： A61K9/20 ,  A61K9/14 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K31/426 ,  A61K31/4418 ,  A61K45/06

摘要： The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonapthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.

公开(公告)号：US20180360761A1

公开(公告)日：2018-12-20

申请号：US15781693

申请日：2016-12-07

申请人： Ardea Biosciences, Inc. ,  AstraZeneca AB

发明人： Joanne REILAND WAKEMAN ,  Colin ROWLINGS ,  Sha LIU ,  Gerry BURKE ,  Christian VON CORSWANT ,  Christer TANNERGREN ,  Johan HJÄRTSTAM

IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K45/06 ,  A61K31/426 ,  A61K31/4418 ,  A61K9/50 ,  A61K9/48

摘要： The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.